We are live on ! Find out more
RP

Regeneron Pharmaceuticals Portfolio holdings

AUM $177M
1-Year Est. Return 9.82%
This Fund
S&P 500
This Quarter Est. Return
-47.75%
1 Year Est. Return
+9.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$33.8M
AUM Growth
-$667M
Cap. Flow
-$636M
Cap. Flow %
-1,880.83%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
–
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$635M
2
ADVM
Adverum Biotechnologies
ADVM
+$820K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTLA icon
1
Intellia Therapeutics
NTLA
$1.67B
$33.3M 98.49%
3,702,995
– –
ACET icon
2
Adicet Bio
ACET
$74.7M
$510K 1.51%
60,511
– –
ADVM
3
DELISTED
Adverum Biotechnologies
ADVM
– –
-180,909
Closed -$820K
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$29.3B
– –
-1,392,303
Closed -$635M

Similar funds

ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return
AGC
Alden Global Capital Brandon, Florida $177M AUM 32.31% 1-Year Est. Return
CTC
Cetera Trust Company St. Paul, Minnesota $177M AUM 28.75% 1-Year Est. Return
ACM
Ararat Capital Management Westport, Connecticut $178M AUM 26.61% 1-Year Est. Return
NRWA
North Ridge Wealth Advisors Beaverton, Oregon $178M AUM 12.81% 1-Year Est. Return
SMTF
Sphera Management Technology Funds Tel Aviv, Israel $178M AUM 42.1% 1-Year Est. Return
XWL
XXI Wealth LLC Chicago, Illinois $177M AUM
MFFIA
McIntyre, Freedman & Flynn Investment Advisers Orleans, Massachusetts $176M AUM 42.57% 1-Year Est. Return

Regeneron Pharmaceuticals's Q4 2025 Portfolio in Review

As of Q4 2025, Regeneron Pharmaceuticals held 4 positions worth $33.8M, down 95% from $700M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Regeneron Pharmaceuticals withdrew a net $636M in Q4 2025, closing 2 positions. Its most notable exit was Alnylam Pharmaceuticals, an estimated $635M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Regeneron Pharmaceuticals fully exited Alnylam Pharmaceuticals in Q4 2025, selling an estimated $635M.
  • Regeneron Pharmaceuticals's ten largest holdings make up 100% of its $33.8M portfolio in Q4 2025.
  • Regeneron Pharmaceuticals opened 0 new positions and closed 2 in Q4 2025.
  • Regeneron Pharmaceuticals's portfolio value fell 95% quarter-over-quarter to $33.8M.

Based on Regeneron Pharmaceuticals's 13F filing for Q4 2025, filed 6 Feb 2026.